<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109343</url>
  </required_header>
  <id_info>
    <org_study_id>V221-019</org_study_id>
    <secondary_id>2005_027</secondary_id>
    <nct_id>NCT00109343</nct_id>
  </id_info>
  <brief_title>V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)</brief_title>
  <official_title>An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The study is being conducted to demonstrate that V221 may be administered concomitantly with
      pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles,
      mumps, rubella, varicella, or the 7 serotypes of S. pneumoniae.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥255 mIU/mL</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving ProQuad™ alone</time_frame>
    <description>Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;255 mIU/mL) to Measles at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥10 Ab Units/mL</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving ProQuad™ alone</time_frame>
    <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;10 ELISA Ab units/mL) to Mumps at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving ProQuad™ alone</time_frame>
    <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;10 IU/mL) to Rubella at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Varicella Antibody Titer ≥1.25 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL and ≥5 gpELISA Units/mL</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving ProQuad™ alone</time_frame>
    <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer &lt;1.25 gpELISA units/mL at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 4 - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 6B - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone.</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 6B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 9V - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 9V</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 14 - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 18C - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 18C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 19F - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 19F</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 23F - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 23F</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 4</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 6B</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 9V</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 14</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 18C</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 19F</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 23F</measure>
    <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1027</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: ProQuad™ (V221) + PREVNAR™ (pneumococcal 7-valent conjugate vaccine) followed by ProQuad™ (Day 91)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: PREVNAR™ followed by ProQuad™ (Day 43) followed by ProQuad™ (Day 133)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3: ProQuad™ followed by PREVNAR™ (Day 43), followed by ProQuad™ (Day 91)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: ProQuad™ (V221)</intervention_name>
    <description>0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>ProQuad™</other_name>
    <other_name>V221</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)</intervention_name>
    <description>0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>PREVNAR™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health

          -  12 to 15 months of age

          -  Negative clinical history to measles, mumps, rubella, varicella and/or zoster

          -  Received only the 3-dose primary series of a pneumococcal conjugate vaccine with at
             least 2 months prior to the receipt of any of the study vaccines

          -  Signed consent

        Exclusion Criteria:

          -  Previous administration of any measles, mumps, rubella, or varicella vaccine either
             alone or in any combination

          -  Any condition resulting in depressed immunity

          -  Any allergy to any vaccine component as stated in the package circulars

          -  Exposure to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the
             study vaccination

          -  History of seizure disorder

          -  Receipt of an inactivated vaccine within 14 days prior to enrollment or live vaccine
             within 30 days

          -  Recent febrile illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>15 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Leonardi M, Bromberg K, Baxter R, Gardner JL, Klopfer S, Nicholson O, Brockley M, Trammel J, Leamy V, Williams W, Kuter B, Schödel F. Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. Pediatrics. 2011 Dec;128(6):e1387-94. doi: 10.1542/peds.2010-2132. Epub 2011 Nov 28.</citation>
    <PMID>22123890</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2005</study_first_submitted>
  <study_first_submitted_qc>April 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2005</study_first_posted>
  <results_first_submitted>September 23, 2009</results_first_submitted>
  <results_first_submitted_qc>January 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2010</results_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>24 clinical sites in the United States
Date first participant visit: 06-Mar-2006
Date last participant visit: 14-Sep-2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - ProQuad™ + PREVNAR™</title>
          <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
          <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
        </group>
        <group group_id="P3">
          <title>Group 3 - ProQuad™ Followed by PREVNAR™</title>
          <description>Group 3 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 1. Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="510"/>
                <participants group_id="P2" count="258"/>
                <participants group_id="P3" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="510"/>
                <participants group_id="P2" count="258"/>
                <participants group_id="P3" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="0">Per-protocol, subjects in Group 1 were not vaccinated at Visit 2</participants>
                <participants group_id="P2" count="246"/>
                <participants group_id="P3" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 4</title>
              <participants_list>
                <participants group_id="P1" count="466"/>
                <participants group_id="P2" count="235"/>
                <participants group_id="P3" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="446"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Moved</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - ProQuad™ + PREVNAR™</title>
          <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
          <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
        </group>
        <group group_id="B3">
          <title>Group 3 - ProQuad™ Followed by PREVNAR™</title>
          <description>Group 3 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 1. Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="510"/>
            <count group_id="B2" value="258"/>
            <count group_id="B3" value="259"/>
            <count group_id="B4" value="1027"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="0.96"/>
                    <measurement group_id="B2" value="12.5" spread="0.93"/>
                    <measurement group_id="B3" value="12.6" spread="0.98"/>
                    <measurement group_id="B4" value="12.6" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥255 mIU/mL</title>
        <description>Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;255 mIU/mL) to Measles at Baseline.</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving ProQuad™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 - ProQuad™ Followed by PREVNAR™</title>
            <description>Group 3 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 1. Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥255 mIU/mL</title>
          <description>Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;255 mIU/mL) to Measles at Baseline.</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥10 Ab Units/mL</title>
        <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;10 ELISA Ab units/mL) to Mumps at Baseline.</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving ProQuad™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 - ProQuad™ Followed by PREVNAR™</title>
            <description>Group 3 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 1. Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥10 Ab Units/mL</title>
          <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;10 ELISA Ab units/mL) to Mumps at Baseline.</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL</title>
        <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;10 IU/mL) to Rubella at Baseline.</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving ProQuad™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 - ProQuad™ Followed by PREVNAR™</title>
            <description>Group 3 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 1. Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL</title>
          <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;10 IU/mL) to Rubella at Baseline.</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Varicella Antibody Titer ≥1.25 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL and ≥5 gpELISA Units/mL</title>
        <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer &lt;1.25 gpELISA units/mL at Baseline</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving ProQuad™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer &lt;1.25 gpELISA units/mL at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 - ProQuad™ Followed by PREVNAR™</title>
            <description>Group 3 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 1. Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Varicella Antibody Titer ≥1.25 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL and ≥5 gpELISA Units/mL</title>
          <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer &lt;1.25 gpELISA units/mL at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer &lt;1.25 gpELISA units/mL at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants ≥1.25 gpELISA units/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374"/>
                    <measurement group_id="O2" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants ≥5 gpELISA units/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 4</title>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 4</title>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403"/>
                    <measurement group_id="O2" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 6B</title>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 6B</title>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408"/>
                    <measurement group_id="O2" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 9V</title>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 9V</title>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407"/>
                    <measurement group_id="O2" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 14</title>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 14</title>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407"/>
                    <measurement group_id="O2" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 18C</title>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 18C</title>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 19F</title>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 19F</title>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407"/>
                    <measurement group_id="O2" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 23F</title>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Pneumococcal Polysaccharide ELISA Titer ≥0.2 mcg/mL for S. Pneumoniae Serotype 23F</title>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412"/>
                    <measurement group_id="O2" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to S. Pneumoniae Serotype 4 – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 4</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 4 – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 4</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" lower_limit="1.41" upper_limit="1.67"/>
                    <measurement group_id="O2" value="1.34" lower_limit="1.19" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to S. Pneumoniae Serotype 6B – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 6B</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone.</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 6B – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 6B</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.17" lower_limit="8.40" upper_limit="10.02"/>
                    <measurement group_id="O2" value="8.22" lower_limit="7.17" upper_limit="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to S. Pneumoniae Serotype 9V – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 9V</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 9V – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 9V</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" lower_limit="2.76" upper_limit="3.21"/>
                    <measurement group_id="O2" value="2.71" lower_limit="2.44" upper_limit="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to S. Pneumoniae Serotype 14 – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 14</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 14 – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 14</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" lower_limit="6.32" upper_limit="7.48"/>
                    <measurement group_id="O2" value="5.61" lower_limit="4.95" upper_limit="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to S. Pneumoniae Serotype 18C – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 18C</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 18C – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 18C</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" lower_limit="2.14" upper_limit="2.58"/>
                    <measurement group_id="O2" value="2.23" lower_limit="1.96" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to S. Pneumoniae Serotype 19F – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 19F</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 19F – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 19F</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" lower_limit="3.31" upper_limit="3.91"/>
                    <measurement group_id="O2" value="3.22" lower_limit="2.85" upper_limit="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to S. Pneumoniae Serotype 23F – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 23F</description>
        <time_frame>6 weeks Postvaccination in subjects receiving ProQuad™ concomitantly with a fourth dose of Prevnar™ and in subjects receiving a fourth dose of Prevnar™ alone</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - ProQuad™ + PREVNAR™</title>
            <description>Group 1 – ProQuad™ (measles, mumps, rubella, and varicella vaccine) + fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered concomitantly at separate injection sites on Day 1. Second dose of ProQuad™ administered at least 90 days (Day 91) after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - PREVNAR™ Followed by ProQuad™</title>
            <description>Group 2 – Fourth dose of PREVNAR™ (pneumococcal 7-valent conjugate vaccine) administered on Day 1. ProQuad™ (measles, mumps, rubella, and varicella vaccine) administered on Day 43. Second dose of ProQuad™ administered at least 90 days (Day 133) after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 23F – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to S. Pneumoniae serotype 23F</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="3.85" upper_limit="4.67"/>
                    <measurement group_id="O2" value="3.71" lower_limit="3.16" upper_limit="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days post-dose</time_frame>
      <desc>The number of participants listed as &quot;at risk&quot; is the number of participants with follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>ProQuad™ + Prevnar™ (After Dose 1)</title>
          <description>ProQuad™ + Prevnar™ (After Dose 1) includes Days 1 to 28 after the first dose of ProQuad™ (safety follow-up period 1 for Group 1)</description>
        </group>
        <group group_id="E2">
          <title>ProQuad™ Alone (After Dose 1)</title>
          <description>ProQuad™ Alone (After Dose 1) includes Days 1 to 28 after the first dose of ProQuad™ (safety follow-up period 1 for Group 3 and safety follow-up period 2 for Group 2).</description>
        </group>
        <group group_id="E3">
          <title>ProQuad™ (After Dose 2)</title>
          <description>ProQuad™ (After Dose 2) includes Days 1 to 28 after the second dose of ProQuad™ (safety follow-up period 3 for Group 1, Group 2, and Group 3).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Pneumonia Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Croup Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neuroblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA Version 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="367" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="311" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="499" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="138" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Otitis Media Acute</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Viral Rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Diaper</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Rash Morbilliform</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Rash Vesicular</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Injection Site Bruising (Prevnar Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema (Prevnar Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Pain (Prevnar Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Rash (Prevnar Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling (Prevnar Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Bruising (ProQuad Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Injection Site Pain (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="163" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Injection Site Rash (ProQuad Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="910"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="495"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="910"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One subject (Group 3-ProQuad™ followed by PREVNAR™) was diagnosed (Day 8) with Stage IV neuroblastoma (considered not related to study vaccine by investigator) and discontinued from the study. Subject died (Day 218) due to neuroblastoma.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

